KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBT Margin (2018 - 2025)

Vir Biotechnology's EBT Margin history spans 8 years, with the latest figure at 67.21% for Q4 2025.

  • For Q4 2025, EBT Margin rose 77872.0% year-over-year to 67.21%; the TTM value through Dec 2025 reached 638.56%, up 11380.0%, while the annual FY2025 figure was 638.56%, 6639.0% up from the prior year.
  • EBT Margin for Q4 2025 was 67.21% at Vir Biotechnology, up from 67905.42% in the prior quarter.
  • Across five years, EBT Margin topped out at 106.9% in Q3 2021 and bottomed at 67905.42% in Q3 2025.
  • The 5-year median for EBT Margin is 647.3% (2022), against an average of 5856.2%.
  • The largest annual shift saw EBT Margin soared 861301bps in 2022 before it crashed -5893315bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 66.45% in 2021, then crashed by -562bps to 306.9% in 2022, then crashed by -134bps to 719.35% in 2023, then decreased by -18bps to 845.93% in 2024, then surged by 92bps to 67.21% in 2025.
  • Per Business Quant, the three most recent readings for VIR's EBT Margin are 67.21% (Q4 2025), 67905.42% (Q3 2025), and 9125.86% (Q2 2025).